2022
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCancer-specific mortalityKaplan-Meier analysisHigh-risk groupImpact of metastasectomyRenal cell carcinomaCell carcinomaMultimodal management strategyPotential prognostic variablesHigh-risk patientsMulticenter retrospective analysisCox regression analysisIntermediate-risk subgroupsMedian OSMRCC patientsCause mortalitySurgical metastasectomyOverall survivalPrimary outcomeSecondary outcomesSpecific survivalCox regressionCancer-SpecificTreatment paradigmMetastasectomyDisparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)
Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCancer-specific mortalityCancer-specific survivalKaplan-Meier analysisCause mortalityOverall survivalMultivariable analysisSurvival outcomesCell carcinomaStage IIIStage IFive-year cancer-specific survivalAfrican AmericansNon-African American patientsRenal cancer databasePapillary renal cell carcinomaOverall survival outcomesAfrican American raceStage III/IV RCCHigher stageIndolent histologiesSecondary outcomesPrimary outcomeRadical nephrectomyPositive margins
2021
Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients
Javier-DesLoges JF, Meagher MF, Walia A, Nguyen MV, Perry JM, Narasimhan RS, Hakimi K, Soliman S, Yuan J, Chakoumakos MA, Ghali F, Patel DN, Wan F, Murphy JD, Derweesh IH. Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients. Urologic Oncology Seminars And Original Investigations 2021, 39: 837.e1-837.e7. PMID: 34580026, DOI: 10.1016/j.urolonc.2021.08.021.Peer-Reviewed Original ResearchConceptsNon-Hispanic white patientsCancer-specific survivalRenal cell carcinomaMedically Underserved AreasCause mortalityWhite patientsHealth care system accessSpecific survivalNon-Hispanic whitesLocalized Renal Cell CarcinomaTertiary referral centerCause mortality riskKaplan-Meier analysisLog-rank testCancer surgical outcomesOverall survivalReferral centerSecondary outcomesPrimary outcomeHispanic patientsMeier analysisCox regressionSurgical outcomesCell carcinomaRisk factorsEvaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act
Javier-DesLoges JF, Yuan J, Soliman S, Hakimi K, Meagher MF, Ghali F, Hsiang W, Patel DN, Kim SP, Murphy JD, Parsons JK, Derweesh IH. Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act. JAMA Network Open 2021, 4: e2116267. PMID: 34269808, PMCID: PMC8285737, DOI: 10.1001/jamanetworkopen.2021.16267.Peer-Reviewed Original ResearchConceptsLow-income patientsRenal cell carcinomaAffordable Care ActACA implementationNonexpansion statesLocalized diseaseAbsolute percentage changeCell carcinomaCancer stageExpansion statesNational Cancer DatabaseProportion of patientsRetrospective cohort analysisInsurance coveragePatient ProtectionCare ActMedicaid expansion statesInsurance coverage statusLow-income adultsEarly RCC detectionExpansion of insuranceSecondary outcomesInsurance statusAdjusted differenceCancer Database
2020
Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis
Patel S, Uzzo R, Larcher A, Peyronnet B, Lane B, Pruthi D, Reddy M, Capitanio U, Joshi S, Noyes S, Eldefrawy A, Ghali F, Meagher M, Hamilton Z, Yim K, Nasseri R, Bradshaw A, Dey S, Kirmiz S, Wan F, Liss M, Bensalah K, Montorsi F, Derweesh I. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer 2020, 18: e723-e729. PMID: 32600941, DOI: 10.1016/j.clgc.2020.05.002.Peer-Reviewed Original ResearchConceptsKaplan-Meier analysisRenal cell carcinomaPT3a renal cell carcinomaRecurrence-free survivalRadical nephrectomyPartial nephrectomyOverall survivalMultivariable analysisCell carcinomaFunctional outcomeDe novo eGFRGlomular filtration rateClinical T stageMulticenter retrospective analysisRisk of recurrenceMulti-institutional analysisPT3a upstagingOncologic outcomesSecondary outcomesPrimary outcomeIndependent predictorsSurvival outcomesT stagePositive marginsPredictive factorsMulticenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma.
Bradshaw A, Ghali F, Miller N, Keiner C, Dutt R, Meagher M, Yim K, Patel D, Uzzo R, Lane B, Capitanio U, Derweesh I. Multicenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 758-758. DOI: 10.1200/jco.2020.38.6_suppl.758.Peer-Reviewed Original ResearchRecurrence-free survivalCancer-specific survivalKaplan-Meier analysisRenal cell carcinomaPT3a renal cell carcinomaOverall survivalMultivariable analysisSecondary outcomesPrimary outcomeCell carcinomaT3a renal cell carcinomaPathologic tumor sizePoor oncologic outcomesRegression multivariable analysisClear cell histologyLog-rank testPre-operative imagingPositive margin rateHigh recurrence rateAdvanced diseaseCell histologyOncologic outcomesVenous involvementMulticenter analysisOS rates